Skip to main content
. 2016 Mar 4;127(20):2489–2497. doi: 10.1182/blood-2015-12-688895

Figure 2.

Figure 2

cTFH are activated and proliferate in patients with active cGVHD. (A) Frequency of ICOShiPD-1hi in cTFH (CXCR5+CD45RA−CD4+ T cells) was determined in different patient groups. (B) Ki67 expression within cTFH (CXCR5+CD45RA−CD4+ T cells) was determined in different patient groups. (C) Positive correlation between proliferation and frequency of highly activated ICOShiPD-1hi cTFH in the active cGVHD group. Black bar represents median value for each group. The Wilcoxon rank-sum test was used in panels A and B. The Spearman test was used in panel C. *P < .05; **P < 10−4. The gating strategy for identifying ICOShiPD-1hi in cTFH is shown in supplemental Figure 1.